MétaCan
Menu
Back to cohort
Record W4413313879 · doi:10.1093/ijnp/pyaf052.134

296. A POPULATION-BASED STUDY ON LONG-TERM MORTALITY RISK ASSOCIATED WITH CLOZAPINE USE AMONG PATIENTS WITH SCHIZOPHRENIA

2025· article· en· W4413313879 on OpenAlexaff
Sherry Kit Wa Chan, Huan Zhou, Hao Luo, Jianing Tang, William G. Honer, Tarun Bastiampillai, Jiayi Zhou, Heidi Taipale, Wing Chung Chang, SF Lui, E H M Lee

Bibliographic record

VenueThe International Journal of Neuropsychopharmacology · 2025
Typearticle
Languageen
FieldMedicine
TopicSchizophrenia research and treatment
Canadian institutionsUniversity of British ColumbiaUniversity of Waterloo
Fundersnot available
KeywordsClozapineSchizophrenia (object-oriented programming)Term (time)PsychiatryMedicinePopulationPsychologyEnvironmental health

Abstract

fetched live from OpenAlex

Abstract Background Patients with schizophrenia had significant elevated mortality risk. Clozapine is effective for treatment-resistant schizophrenia, but its use is limited because of side effects. Understanding its association with mortality risk in schizophrenia population is crucial. Though meta-analysis reported clozapine use is associated with a significant reduction in all-cause mortality mainly for patients who are continuously treated with clozapine, inconsistent results were reported in more recent studies. Furthermore, few studies reported on relationship of clozapine use and specific cause of mortality including suicide. Aims & Objectives To investigate the association of clozapine with all-cause and cause-specific mortality risk in patients with schizophrenia. Method This 18-year population-based cohort study retrieved records of schizophrenia patients from the electronic clinical records of all public hospitals in Hong Kong. Clozapine users (ClozUs) comprised schizophrenia patients who initiated clozapine treatment between 2003 and 2012, with the index date set at clozapine initiation. Comparators were non-clozapine antipsychotic users (Non-ClozUs) of the same diagnosis without a clozapine prescription ever. They were 1:2 propensity-score matched with demographic characteristics and physical and psychiatric comorbidities. ClozUs were further defined according to the continuation of clozapine use and co-prescribed with other antipsychotics (polypharmacy). Accelerated failure time (AFT) models were applied to estimate the risk of all-cause and cause-specific mortalities (i.e., suicide, cardiovascular disease, infection, and cancer). Results This study included 9,456 individuals, with 2,020 continuous ClozUs (mean [SD] age at the index date, 37.54 [12.42] years; 49.6% females; median [IQR] follow-up time, 12.30 [9.72–15.10] years), 1,132 discontinuous users (40.67 [13.01] years; 53.45% females; 12.61 [10.05–15.45] years), and 6,304 Non-ClozUs (39.37 [13.01] years; 50.6% females; 12.36 [9.73–15.19] years). Using adjusted AFT models accounted for Bonferroni Correction, continuous ClozUs exhibited a lower risk of suicide mortality (AF, 3.01, 99% CI, 1.41–6.44) compared to continuous Non-ClozUs. Continuous clozapine polypharmacy exhibited a lower risk of suicide mortality (3.67; 1.41–9.60) and all-cause mortality (1.42; 1.07–1.88) compared to continuous Non-ClozUs. Discussion & Conclusions These results add to the existing evidence on clozapine’s effectiveness, particularly its anti-suicide effects, and emphasize the need for continuous clozapine use for suitable patients and the possible benefit of clozapine polypharmacy.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.033
Threshold uncertainty score0.066

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.002
Bibliometrics0.0010.002
Science and technology studies0.0010.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.024
GPT teacher head0.349
Teacher spread0.325 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueThe International Journal of NeuropsychopharmacologySame topicSchizophrenia research and treatmentFrench-language works237,207